Integrated Omics Analysis of Pain: Omics Data Generation Center

点击翻译按钮获取中文摘要

SUMMARY The goal of the WF ODGC is to generate metabolomics and lipidomics data on plasma samples collected from participants of the A2CPS Consortium, and to discover novel metabolomic and/or lipidomic signatures that are associated with the conversion from acute to chronic pain. We use high resolution HILIC-MS/MS and high resolution GC-MS for the characterization of metabolites, and charged surface hybrid liquid chromatography- high resolution accurate mass MS/MS in positive and negative electrospray mode to characterize plasma lipids. The ODGC is a collaboration between the Center for Precision Medicine at the Wake Forest University School of Medicine and the West Coast Metabolomics Center at the University of California at Davis. This request for an Administrative Supplement is necessitated by the unforeseen delay in patient recruitment and enrollment at the two Clinical sites, MCC1 and MCC2, and the resulting delay in sample analysis at the ODGC. Based on the estimates from the MCCs, it is anticipated that all samples for metabolomics and lipidomics analysis (8400 samples total) will be collected by the end of August 2025, and analysis, data and sample transfer will be completed by the ODGC by the end of May, 2026. The requested supplement will ensure the successful analysis of the entire complement of samples, characterization and quantification of preselected secondary biomarkers, and integration of the resulting biomarker data with other biomarker information collected for the Consortium.